Luteolin and luteolin-7-O-glucoside protect against acute liver injury through regulation of inflammatory mediators and antioxidative enzymes in GalN/LPS-induced hepatitic ICR mice

다국어 초록 (Multilingual Abstract)

BACKGROUND/OBJECTIVES: Anti-inflammatory and antioxidative activities of luteolin and luteolin-7-O-glucoside were compared in galactosamine (GalN)/lipopolysaccharide (LPS)-induced hepatitic ICR mice.
MATERIALS/METHODS: Male ICR mice (6 weeks old) were divided into 4 groups: normal control, GalN/LPS, luteolin, and luteolin-7-O-glucoside groups. The latter two groups were administered luteolin or luteolin-7-O-glucoside (50 mg/kg BW) daily by gavage for 3 weeks after which hepatitis was induced by intraperitoneal injection of GalN and LPS (1 g/kg BW and 10 μg/kg BW, respectively).
RESULTS: GalN/LPS produced acute hepatic injury by a sharp increase in serum AST, ALT, and TNF-α levels, increases that were ameliorated in the experimental groups. In addition, markedly increased expressions of cyclooxygenase (COX)-2 and its transcription factors, nuclear factor (NF)-κB and activator protein (AP)-1, were also significantly attenuated in the experimental groups. Compared to luteolin-7-O-glucoside, luteolin more potently ameliorated the levels of inflammatory mediators. Phase II enzymes levels and NF-E2 p45-related factor (Nrf)-2 activation that were decreased by GalN/LPS were increased by luteolin and luteolin-7-O-glucoside administration. In addition, compared to luteolin, luteolin-7-O-glucoside acted as a more potent inducer of changes in phase II enzymes. Liver histopathology results were consistent with the mediator and enzyme results.
CONCLUSION: Luteolin and luteolin-7-O-glucoside protect against GalN/LPS-induced hepatotoxicity through the regulation of inflammatory mediators and phase II enzymes.

참고문헌 (Reference)

1 Murota K, "Unique uptake and transport of isoflavone aglycones by human intestinal caco-2 cells: comparison of isoflavonoids and flavonoids" 132 : 1956-1961, 2002

2 Dejager L, "Tumor necrosis factor alpha mediates the lethal hepatotoxic effects of poly(I:C) in D-galactosamine-sensitized mice" 42 : 55-61, 2008

3 Jiang W, "Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll-like receptor 4 expression on macrophages" 102 : 17077-17082, 2005

4 Hossen MJ, "Thymoquinone: an IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities" 7 : 42995-, 2017

5 Izumi T, "Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans" 130 : 1695-1699, 2000

6 Lee JP, "Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils" 31 : 831-838, 2010

7 Lee WC, "Protective effects of luteolin against apoptotic liver damage induced by D-galactosamine/lipopolysaccharide in mice" 74 : 1916-1921, 2011

8 Mao J, "Protective effects of costunolide against D-galactosamine and lipopolysaccharide-induced acute liver injury in mice" 9 : 1469-, 2018

9 Sajadimajd S, "Oxidative stress and cancer: the role of Nrf2" 18 : 538-557, 2018

10 Wu YH, "Nature and mechanisms of hepatocyte apoptosis induced by D-galactosamine/lipopolysaccharide challenge in mice" 33 : 1498-1506, 2014

11 Fujioka S, "NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity" 24 : 7806-7819, 2004

12 Surh YJ, "Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation" 480-481 : 243-268, 2001

13 Kure A, "Metabolic fate of luteolin in rats: its relationship to anti-inflammatory effect" 64 : 4246-4254, 2016

14 Jia Z, "Luteolin protects against vascular inflammation in mice and TNF-alpha-induced monocyte adhesion to endothelial cells via suppressing IΚBα/NF-κB signaling pathway" 26 : 293-302, 2015

15 Fei J, "Luteolin inhibits IL-1β-induced inflammation in rat chondrocytes and attenuates osteoarthritis progression in a rat model" 109 : 1586-1592, 2019

16 Song YS, "Luteolin and luteolin-7-O-glucoside strengthen antioxidative potential through the modulation of Nrf2/MAPK mediated HO-1 signaling cascade in RAW 264.7 cells" 65 : 70-75, 2014

17 박충무, "Luteolin and luteolin-7-O-glucoside inhibit lipopolysaccharide-induced inflammatory responses through modulation of NF-κB/AP-1/PI3K-Akt signaling cascades in RAW 264.7 cells" 한국영양학회 7 (7): 423-429, 2013

18 박충무, "Luteolin Inhibits Inflammatory Responses by Downregulating the JNK, NF-κB, and AP-1 Pathways in TNF-α Activated HepG2 Cells" 한국식품과학회 21 (21): 279-283, 2012

19 Nowak M, "LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-α and the TNF-p55 receptor" 278 : R1202-R1209, 2000

20 Andlauer W, "Isoflavones from tofu are absorbed and metabolized in the isolated rat small intestine" 130 : 3021-3027, 2000

21 Zhou P, "Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin" 56 : 296-300, 2008

22 Shimoi K, "Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans" 438 : 220-224, 1998

23 Kim YW, "Inflammation and oxidative stress in angiogenesis and vascular disease" 91 : 323-328, 2013

24 Richelle M, "Hydrolysis of isoflavone glycosides to aglycones by beta-glycosidase does not alter plasma and urine isoflavone pharmacokinetics in postmenopausal women" 132 : 2587-2592, 2002

25 Ferencíková R, "Hepatotoxic effect of D-galactosamine and protective role of lipid emulsion" 52 : 73-78, 2003

26 Hollman PC, "Health effects and bioavailability of dietary flavonols" 31 (31): S75-S80, 1999

27 Piskula MK, "Factors affecting flavonoids absorption" 12 : 175-180, 2000

28 Zhang M, "Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection" 100 : 30-47, 2013

29 Shanmugam S, "Effects of luteolin and quercetin 3-β-d-glucoside identified from Passiflora subpeltata leaves against acetaminophen induced hepatotoxicity in rats" 83 : 1278-1285, 2016

30 Ross JA, "Dietary flavonoids: bioavailability, metabolic effects, and safety" 22 : 19-34, 2002

31 Kemelo MK, "D-galactosamine/lipopolysaccharide-induced hepatotoxicity downregulates sirtuin 1 in rat liver: role of sirtuin 1 modulation in hepatoprotection" 63 : 615-623, 2014

32 Zubik L, "Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women" 77 : 1459-1465, 2003

33 Rowland I, "Bioavailability of phyto-oestrogens" 89 (89): S45-S58, 2003

34 Kano M, "Bioavailability of isoflavones after ingestion of soy beverages in healthy adults" 136 : 2291-2296, 2006

35 Seelinger G, "Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin" 74 : 1667-1677, 2008

36 Aziz N, "Anti-inflammatory effects of luteolin: a review of in vitro, in vivo, and in silico studies" 225 : 342-358, 2018

37 Hossen MJ, "AP-1-targeted inhibition of macrophage function and lipopolysaccharide/D-galactosamineinduced hepatitis by Phyllanthus acidus methanolic extract" 43 : 1137-1158, 2015